SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published article

18 Oct 2013 07:00

RNS Number : 8024Q
Tristel PLC
18 October 2013
 



Tristel plc

("Tristel" or "the Company")

 

Peer-reviewed published article supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of an article in a peer-reviewed journal that describes the benefits of Tristel products.

 

The study is titled "A randomised single-blind comparison of the effectiveness of the high-level disinfectants Tristel Fuse (chlorine dioxide) and Cidex OPA (ortho-phthaldehyde) for use with flexible cystoscopes". It has been published in The British Journal of Urology International (on line 10.1111 BJU 12208) and will be published within the Urological Society of Australia and New Zealand (special issue volume 112).

 

The article compares the effectiveness, safety and cost of Tristel's chlorine dioxide Fuse chemistry with Cidex OPA (Johnson & Johnson, USA), in an automated endoscope reprocessor (Medivators Inc, USA) for high level disinfection of flexible cystoscopes.

 

Tristel Fuse, which was used within the Company's Stella decontamination system, was found to be as effective, more economic and easier for the nursing staff to use than the American products with which it was compared.

 

Tristel CEO, Paul Swinney, commented: "This study was initiated in 2009 by the Department of Urology, Tauranga Hospital, New Zealand, and the initial results were reported at the Societe Internationale d'Urologie congress, Shanghai, 2011.

 

"This is the first published study that compares our Tristel Fuse and Stella system with one of the world's leading combinations of disinfectant and endoscope washing machine. It demonstrates that our chlorine dioxide technology is just as safe and effective as the world's most widely used medical instrument disinfectant, whilst producing cost savings for hospitals.

 

"This study joins the growing body of published scientific evidence demonstrating that Tristel products are superior to the incumbent technologies still being used around the world."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRANKODPPBDDDKD
Date   Source Headline
23rd Feb 20224:45 pmRNSInterim dividend confirmation
22nd Feb 202211:30 amRNSDirector/PDMR Shareholding
21st Feb 20224:40 pmRNSSecond Price Monitoring Extn
21st Feb 20224:35 pmRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSHalf-year Report
17th Feb 20223:00 pmRNSIssue of Equity
1st Feb 20227:00 amRNSConfirmation of Interim Results
13th Dec 20215:13 pmRNSResult of AGM
13th Dec 20217:00 amRNSAGM Statement and notice of results
27th Oct 20217:00 amRNSDirector/PDMR Shareholding
21st Oct 20214:39 pmRNSDirector/PDMR Shareholding
19th Oct 20215:35 pmRNSHolding(s) in Company
18th Oct 20213:50 pmRNSIssue of Equity
18th Oct 202111:59 amRNSDirector/PDMR Shareholding
18th Oct 20217:00 amRNSFinal Results
12th Oct 20215:58 pmRNSHolding(s) in Company
22nd Sep 20217:00 amRNSNotice of Results
23rd Aug 20217:00 amRNSIssue of Equity
10th Aug 20217:00 amRNSIssue of Equity
29th Jul 20216:29 pmRNSTR1: Notification of Major Holdings
21st Jul 20217:00 amRNSTrading update
9th Jul 20211:21 pmRNSIssue of Equity
24th Jun 20217:00 amRNSRegulatory approval for EPA, Canada & South Korea
8th Jun 20217:00 amRNSIssue of Equity
13th May 20213:30 pmRNSIssue of Equity
26th Apr 20213:15 pmRNSDirector/PDMR Shareholding
26th Apr 20212:06 pmRNSSecond Price Monitoring Extn
26th Apr 20212:00 pmRNSPrice Monitoring Extension
26th Apr 202111:05 amRNSSecond Price Monitoring Extn
26th Apr 202111:00 amRNSPrice Monitoring Extension
26th Apr 20217:00 amRNSTrading Update
21st Apr 20213:00 pmRNSIssue of Equity
19th Apr 20211:00 pmRNSIssue of Equity
6th Apr 20211:00 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSTotal Voting Rights
26th Mar 202110:40 amRNSIssue of Equity
4th Mar 20217:00 amRNSDirector/PDMR Shareholding
1st Mar 20215:00 pmRNSDirector/PDMR Shareholding and Issue of Equity
22nd Feb 20217:00 amRNSHalf-year Report
18th Feb 202111:15 amRNSNotice of investor presentation
15th Feb 202111:00 amRNSIssue of Equity
29th Jan 20217:00 amRNSIssue of Equity
14th Jan 20212:00 pmRNSExercise of Options
24th Dec 20207:00 amRNSDirector Appointment
15th Dec 202011:39 amRNSResult of AGM
15th Dec 20207:00 amRNSAGM Statement and notice of results
2nd Dec 20202:00 pmRNSUpdate to Executive Performance Share Plan 2021
2nd Dec 202010:30 amRNSTristel wins AIM Growth Business of the Year Award
9th Nov 20209:49 amRNSExercise of Options
2nd Nov 202010:30 amRNSQ&A update following preliminary results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.